2017. ASCO Annual Meeting – Non-progression during avelumab treatment is associated with clinically relevant improvements in health-related quality of life in patients with Merkel Cell Carcinoma

Bharmal M, Fofana F, Mahnke L, Schlichting M, Kaufman HL. Non-progression during avelumab treatment is associated with clinically relevant improvements in health-related quality of life in patients with Merkel Cell Carcinoma. JCO May 2017;35(15_suppl):e201070. Presented at: ASCO 2017; June 2-6, 2017: Chicago, IL, USA.